These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20932675)

  • 41. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
    Cheng JC; Schultheiss TE; Nguyen KH; Wong JY
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):351-7. PubMed ID: 18164841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan.
    Nihei K; Ogino T; Ishikura S; Kawashima M; Nishimura H; Arahira S; Onozawa M
    Jpn J Clin Oncol; 2005 Dec; 35(12):745-52. PubMed ID: 16314345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization.
    Woel R; Beard C; Chen MH; Hurwitz M; Loffredo M; McMahon E; Ching J; Lopes L; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):392-6. PubMed ID: 15890580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
    Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.
    Karlsdóttir A; Johannessen DC; Muren LP; Wentzel-Larsen T; Dahl O
    Radiother Oncol; 2004 Apr; 71(1):43-53. PubMed ID: 15066295
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma.
    Zelefsky MJ; Leibel SA; Kutcher GJ; Kelson S; Ling CC; Fuks Z
    Cancer J Sci Am; 1995; 1(2):142-50. PubMed ID: 9166467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
    Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
    Arcangeli S; Strigari L; Soete G; De Meerleer G; Gomellini S; Fonteyne V; Storme G; Arcangeli G
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):39-45. PubMed ID: 18538488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Late gastrointestinal and urogenital side-effects after radiotherapy--incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer.
    Schmid MP; Pötter R; Bombosch V; Sljivic S; Kirisits C; Dörr W; Goldner G
    Radiother Oncol; 2012 Jul; 104(1):114-8. PubMed ID: 22727264
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer.
    Mendenhall NP; Li Z; Hoppe BS; Marcus RB; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Costa J; Henderson R
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):213-21. PubMed ID: 21093164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Salvage intensity-modulated radiation therapy for locally recurrent prostate cancer after cryotherapy.
    Choi M; Kim CR; Hung AY
    Clin Genitourin Cancer; 2013 Jun; 11(2):85-8. PubMed ID: 23041454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute and Late Genitourinary Toxicity after 72 Gy of Conventionally Fractionated Conformal Radiotherapy for Localised Prostate Cancer: Impact of Individual and Clinical Parameters.
    Stankovic V; Džamic Z; Pekmezovic T; Tepavcevic DK; Dozic M; Saric M; Vuckovic S; Nikitovic M
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):577-86. PubMed ID: 27184943
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer.
    Coen JJ; Paly JJ; Niemierko A; Weyman E; Rodrigues A; Shipley WU; Zietman AL; Talcott JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e201-9. PubMed ID: 21621343
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions.
    Okada T; Tsuji H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Tsujii H;
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):968-72. PubMed ID: 22898380
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diabetes mellitus: a predictor for late radiation morbidity.
    Herold DM; Hanlon AL; Hanks GE
    Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):475-9. PubMed ID: 10078625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimal local control and tolerability of three-dimensional conformal radiation therapy in prostate cancer: a single institutional experience of dose escalation in 125 patients.
    Ferrera G; Caminiti G; Grillo A; Alongi F; Evangelista G; Greco E; Cucchiara T; Bono M; Mortellaro G; Cirrincione A; Dalia F; Iacoviello G; Caputo V; Midiri M; Sciumè F
    Tumori; 2013; 99(6):676-81. PubMed ID: 24503790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
    Michalski JM; Winter K; Purdy JA; Wilder RB; Perez CA; Roach M; Parliament MB; Pollack A; Markoe AM; Harms W; Sandler HM; Cox JD
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):192-8. PubMed ID: 12694838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.